metformin has been researched along with Hereditary Breast and Ovarian Cancer Syndrome in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hereditary Breast and Ovarian Cancer Syndrome: Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walcott, FL | 1 |
| Patel, J | 1 |
| Lubet, R | 1 |
| Rodriguez, L | 1 |
| Calzone, KA | 1 |
1 review available for metformin and Hereditary Breast and Ovarian Cancer Syndrome
| Article | Year |
|---|---|
Hereditary cancer syndromes as model systems for chemopreventive agent development.
Topics: Adaptor Proteins, Signal Transducing; Adenomatous Polyposis Coli; Adenosine Triphosphatases; Animals | 2016 |